163042-96-4
163042-96-4
Chemical Structure
Namodenoson
Synonym(s): CF-102; 2-Cl-IB-MECA
- CAS No.: 163042-96-4
- Formula:C18H18ClIN6O4
- Molecular Weight:544.73
IUPAC Name: (2S,3S,4R,5R)-5-(2-chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide
InChIKey: IPSYPUKKXMNCNQ-PFHKOEEOSA-N
SMILES: ClC1=NC(NCC2=CC=CC(I)=C2)=C3N=CN([C@@H]4O[C@H](C(NC)=O)[C@@H](O)[C@H]4O)C3=N1
Biological Activity: Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist (Ki=0.33 nM). Namodenoson displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Namodenoson | 99.56% | Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist (Ki=0.33 nM). Namodenoson displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Namodenoson (Standard) | ≥98% | Namodenoson (Standard) is the analytical standard of Namodenoson. This product is intended for research and analytical applications. Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist (Ki=0.33 nM). Namodenoson displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauro-obeticholic acid-d5 | Tauro-obeticholic acid-d5 is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Van Schaick EA et al. Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol. 1996 Jul 25;308(3):311-4. [Content Brief]
- [2]. Jacobson KA et al. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998 May;19(5):184-91. [Content Brief]
